“The biomedical field fully reflects the technological progress and asset energy is in vitro diagnostics, from the initial technical strength of the lower biochemical class, the key sales market is secondary hospitals, followed by in vitro diagnostics, which have many listed companies in recent years, followed by molecular diagnostics and POCT (just-in-time testing), which is also the current sales market growth rate is faster, but also the industry technical strength of the largest.” A pharmaceutical investment banking personnel in the admission of the “Securities Daily” reporter interview indicates that in vitro diagnostics in recent years more access to the financial market’s affection.
From the launch process of in vitro diagnostic companies can be seen, the initial phase is dominated by biochemical companies, such as Daan Gene, Dean Diagnostics and Meikang Biology, etc. After 2016, immunity and molecular diagnostic companies such as Antu Biology, Kepu Biology and Minde Biology gradually logged into the A-share market one after another, while the total number of biochemical companies gradually decreased. Among the companies listed on the science and technology board, Haoobo has the more adequate 4G immunoassay technology at this stage in China; Pumen Technology’s in vitro diagnostic product line key development trend of electrochemiluminescence immunity profiling technology program; Heatscape Biology is the only company that has completed the use of optical materials in immunity profiling technology and completed industrial development at this stage in China; ShuoShi Biology was the first to advocate molecular diagnostics The company is the only company in China that has completed the technological development of the use of optical materials for immunity profiling.
In vitro diagnostics is the number one market segment in the field of medical devices, thanks to the rapid development trend of scientific and technological progress, especially the significant progress in contemporary biotechnology, monoclonal antibodies technicality, electro-optical solution technicality, etc., which prompted the in vitro diagnostic industry to connect from the field of molecular biology to biology, and the test accuracy is improved while the test cycle time is significantly reduced, which also further reduces the test cost. At the same time, the test cycle time has been significantly reduced and the test cost has been further reduced. Such elements are driving the development trend of in vitro diagnostic industry from empirical to precise and from high cost to low cost in rapid iteration.
According to the statistical analysis of Prospect Industry Research Institute, the core orientation of China’s in vitro diagnostic sales market has long been gradually migrating from biochemical confirmatory diagnosis to immune diagnosis and molecular diagnosis, and from 2010 to 2017, the market size of biochemical confirmatory diagnosis in China’s in vitro diagnostic sales market decreased from 27% to 19%, the market size of immune diagnosis increased from 27% to 36%, and molecular diagnosis also increased from 5% to 16%. With a large number of companies entering the in vitro diagnostic field with higher technical requirements, the rapid development of the in vitro diagnostic industry in China is slowly changing from the improvement of “quantity” to the development trend of “quality”, and the technical transformation is the main driving force to promote the development trend of the in vitro diagnostic industry. The main driving force for the development of in vitro diagnostic industry.
As medical and health equipment and devices in the in vitro diagnostic industry, immunodiagnosis, molecular diagnosis and POCT mean the future development trend of the industry. In the research report, GZHS emphasizes that among the five in vitro diagnostic science and technology board listed trial companies, four companies have improved their main business income by RMB 200 million in 2018, with an average operating income growth rate of 29.33%, all of which have achieved a certain scale of operation, and landing on the science and technology board can fund the assets required for the future development and growth trend of the company, enhance the allocation of resources and improve the competitive ability.